January 31, 2022

Top Stocks to Buy Now? 3 Biotech Stocks for your Watchlist | BioPub

Midas Letter
Midas Letter
Top Stocks to Buy Now? 3 Biotech Stocks for your Watchlist | BioPub

BioPub is a small-cap biotech investing website, where PhDs and MDs deliberate daily about biotech, medical and investment questions. The website’s goal is to be the secret weapon and unfair advantage of every subscriber. They are looking for emerging, leading-edge science that will permanently change medicine – the top stocks in biotech to add to your watchlist or even buy now.

“Most of the biotech investments out there are not investment grade when you look at them through strenuous eyes. We focus on finding those things flying below the radar that are special situations, unrecognized gems. Typical market cap 100 million, where we think the science is just extraordinary, a breakout is looming and it’s just not been noticed yet. I think we’ve done pretty well. – BioPub.co Founder Dr. Mark Swaim

The website does not feature companies unless they have interviewed management and scrutinized their basic science and clinical ramifications. On that note, the website founder highlights three little-known biotech companies he foresees will succeed, and investors may find value.

AcuRx Pharmaceuticals (NASDAQ:ACXP)

AcuRx Pharma is promulgating the first new class of antibiotics for human use in 30 years. Its lead agent, ibezapolstat, is a novel chemical entity and first-in-class agent that could become first-line therapy, orally, for Clostridoides difficile enterocolitis – a resistant, hard to kill GI tract infection common in hospitalized patients receiving antibiotics. The drug is currently undergoing clinical trials.

Medicenna Therapeutics Corp (NASDAQ:MDNA, TSE:MDNA)

Medicenna has created a highly novel therapeutic that extends survival in glioblastoma multiforme cancer patients by 150%. The company is advancing to market a bespoke version of interkeukin-2 with no toxicity while enhancing the immune system.


NervGen Pharma is in the process of developing NVG-291, a clinical-stage candidate to treat spinal cord injuries, multiple sclerosis and Alzheimer’s disease,
The drug may treat not only spinal cord injury with the restoration of gait but also multiple sclerosis, traumatic brain injury, Alzheimer’s dementia, stroke, Havana syndrome, and Parkinson’s disease.


00:00 – Biopub.co Founder Dr Mark Swaim
00:41 – Biopub value proposition for subscribers
02:49 – AcuRx Pharmaceuticals (NASDAQ:ACXP)
07:08 – Medicenna (NASDAQ:MDNA)
11:51 – NervGen Pharma Corp (TSX-V:NGEN)

Related Articles


Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.